Novel nanotechnology-enabled system for endovascul.. (CosmoPHOS-nano)
Novel nanotechnology-enabled system for endovascular in vivo near-infrared fluorescence molecular imaging and endovascular near-infrared targeted photodynamic therapy of atherosclerotic heart disease
Start date: Mar 1, 2013,
End date: Feb 28, 2018
CosmoPHOS-nano is a multidisciplinary, translational and business-oriented project, aiming to accomplish the following objectives:1) develop the CosmoPHOS system, which is a novel theranostic (diagnostic & therapeutic) nanotechnology-enabled portable combination system enabling endovascular in vivo near-infrared fluorescence molecular imaging, endovascular near-infrared targeted photodynamic therapy, real-time & follow-up therapy monitoring of atherosclerotic coronary artery disease (CAD),2) nonclinically evaluate this system,3) clinically validate the system after regulatory approval, &4) reduce in the long-term CAD deaths and morbidity by up to 40%, resulting in a significant decrease of the European and global healthcare costs for CAD, increasing the income of the European healthcare industry from CAD market which is the global largest. The CosmoPHOS-nano consortium has a five year history of successful collaboration between the industrial and academic partners, and its funding would underpin a team devoted to delivering a novel powerful & affordable healthcare solution against the leading cause of death, without the need for heavy and expensive medical equipment.The CosmoPHOS system consists of two interacting components:a) targeted theranostic near-infrared photoactivatable biocompatible nanomedicines, andb) medical devices.After systemic administration, the nanomedicines targeted accumulate in coronary atherosclerotic plaques, followed by endocoronary photoactivation and detection by the medical devices, enabling molecular imaging, targeted therapy, real-time & follow-up therapy monitoring of CAD. Preliminary in vitro & in vivo successful experimental results, as well as parts of the CosmoPHOS system are already available from the prior five year collaboration.The project plan includes: A) nonclinical R&D (30 months); B) nonclinical validation & regulatory approval (18 months); C) first-in-man phase-I clinical trial in 20 CAD patients (12 months).
Get Access to the 1st Network for European Cooperation